{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:48:26Z","timestamp":1790894906633,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000723","name":"Tenovus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjanaesthesia.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Anaesthesia"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bja.2020.05.017","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T17:03:49Z","timestamp":1592586229000},"page":"159-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland"],"prefix":"10.1016","volume":"125","author":[{"given":"Nicola","family":"Torrance","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abirami","family":"Veluchamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma H.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilidh","family":"Moir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Donnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Colvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bja.2020.05.017_bib1","series-title":"British national formulary (BNF)","year":"2016"},{"key":"10.1016\/j.bja.2020.05.017_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","article-title":"Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment","volume":"10","author":"Breivik","year":"2006","journal-title":"Eur J Pain"},{"key":"10.1016\/j.bja.2020.05.017_bib3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic pain in the general population: a systematic review of epidemiological studies","volume":"155","author":"van Hecke","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.bja.2020.05.017_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.ajp.0000210956.31997.89","article-title":"Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community","volume":"23","author":"Smith","year":"2007","journal-title":"Clin J Pain"},{"key":"10.1016\/j.bja.2020.05.017_bib5","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.pain.2014.07.001","article-title":"Estimating the burden of disease in chronic pain with and without neuropathic characteristics: does the choice between the EQ-5D and SF-6D matter?","volume":"155","author":"Torrance","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.bja.2020.05.017_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bja.2020.05.017_bib7","article-title":"Neuropathic pain \u2013pharmacological management. The pharmacological management of neuropathic pain in adults in non-specialist settings","volume":"173","year":"2017","journal-title":"NICE Clin Guidel"},{"key":"10.1016\/j.bja.2020.05.017_bib8","article-title":"Management of chronic pain","year":"1999","journal-title":"A\u00a0Natl Clin Guidel"},{"key":"10.1016\/j.bja.2020.05.017_bib9","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.2018.12358","article-title":"Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993-2017","volume":"320","author":"Montastruc","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.bja.2020.05.017_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2296-14-28","article-title":"An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population","volume":"14","author":"Hall","year":"2013","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.bja.2020.05.017_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ejp.520","article-title":"Changes in opioid and other analgesic use 1995-2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland","volume":"19","author":"Ruscitto","year":"2015","journal-title":"Eur J Pain"},{"key":"10.1016\/j.bja.2020.05.017_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid use in the United States 2002 through 2015","volume":"178","author":"Johansen","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.bja.2020.05.017_bib13","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/pm\/pnw351","article-title":"Impact of unrestricted access to pregabalin on the use of opioids and other CNS-active medications: a cross-sectional time series analysis","volume":"18","author":"Kwok","year":"2017","journal-title":"Pain Med"},{"key":"10.1016\/j.bja.2020.05.017_bib14","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.0000000000002446","article-title":"Antiepileptic use for epilepsy and nonepilepsy disorders: a population-based study (1998-2013)","volume":"86","author":"Leong","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.bja.2020.05.017_bib15","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00228-016-2092-3","article-title":"Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders\u2013a pharmacoepidemiological study and clinical implications","volume":"72","author":"Baftiu","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bja.2020.05.017_bib16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ijcp.12182","article-title":"Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment","volume":"68","author":"Wettermark","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.bja.2020.05.017_bib17","first-page":"83","article-title":"Trends, patient and prescriber characteristics in gabapentinoid use in a sample of United States ambulatory care visits from 2003 to 2016","volume":"9","author":"Zhou","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.bja.2020.05.017_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain \u2013 is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bja.2020.05.017_bib19","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00296-011-2263-6","article-title":"A\u00a0turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity","volume":"32","author":"Conaghan","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.bja.2020.05.017_bib20","doi-asserted-by":"crossref","first-page":"m114","DOI":"10.1136\/bmj.m114","article-title":"Gabapentinoids: has reclassification really solved the problem?","volume":"368","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2020.05.017_bib21","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.bja.2020.05.017_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000355268","article-title":"Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers","volume":"20","author":"Baird","year":"2014","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.bja.2020.05.017_bib23","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain \u2013 United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.bja.2020.05.017_bib24","doi-asserted-by":"crossref","first-page":"l2147","DOI":"10.1136\/bmj.l2147","article-title":"Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden","volume":"365","author":"Molero","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2020.05.017_bib25","author":"National Records of Scotland (NRS)"},{"key":"10.1016\/j.bja.2020.05.017_bib27","doi-asserted-by":"crossref","first-page":"k4364","DOI":"10.1136\/bmj.k4364","article-title":"Pregabalin and gabapentin become controlled drugs to cut deaths from misuse","volume":"363","author":"Mayor","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.bja.2020.05.017_bib28","author":"UK Government Home Office"},{"key":"10.1016\/j.bja.2020.05.017_bib29","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/ije\/dyw060","article-title":"Data resource profile: the scottish national prescribing information System (PIS)","volume":"45","author":"Alvarez-Madrazo","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.bja.2020.05.017_bib30","author":"Office of National Statistics (ONS)"},{"key":"10.1016\/j.bja.2020.05.017_bib32","series-title":"Drug deaths in Tayside, Scotland. 2018 annual report","year":"2019"},{"key":"10.1016\/j.bja.2020.05.017_bib33","article-title":"Trends in opioid use and dosing among socio-economically disadvantaged patients","volume":"5","author":"Gomes","year":"2011","journal-title":"Open Med"},{"key":"10.1016\/j.bja.2020.05.017_bib35","author":"NHS Digital"},{"key":"10.1016\/j.bja.2020.05.017_bib36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S2215-0366(19)30331-1","article-title":"Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England","volume":"6","author":"Marsden","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bja.2020.05.017_bib37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.bja.2018.02.022","article-title":"Association of opioid prescribing practices with chronic pain and benzodiazepine co-prescription: a primary care data linkage study","volume":"120","author":"Torrance","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2020.05.017_bib38","first-page":"281","article-title":"The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey","volume":"7","author":"Torrance","year":"2006","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.bja.2020.05.017_bib39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bja.2020.05.017_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.bja.2020.05.017_bib42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.drugpo.2007.09.005","article-title":"Addressing the wider determinants of problematic drug use: advantages of whole-population over targeted interventions","volume":"19","author":"Bonell","year":"2008","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.bja.2020.05.017_bib43","author":"Scottish Government Health and Social Care"},{"key":"10.1016\/j.bja.2020.05.017_bib44","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s00228-013-1578-5","article-title":"Pregabalin abuse among opiate addicted patients","volume":"69","author":"Grosshans","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bja.2020.05.017_bib45","doi-asserted-by":"crossref","first-page":"l5823","DOI":"10.1136\/bmj.l5823","article-title":"Opioid prescribing is rising in many countries","volume":"367","author":"Smith","year":"2019","journal-title":"BMJ"}],"container-title":["British Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091220303731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091220303731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T18:56:34Z","timestamp":1757789794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007091220303731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0007091220303731"],"URL":"https:\/\/doi.org\/10.1016\/j.bja.2020.05.017","relation":{},"ISSN":["0007-0912"],"issn-type":[{"value":"0007-0912","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland","name":"articletitle","label":"Article Title"},{"value":"British Journal of Anaesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2020.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 British Journal of Anaesthesia. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}